Tirzepatide: Dosage & Administration
Part of the Tirzepatide Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
FDA-Approved Dosing
| Phase | Dose | Duration |
|---|---|---|
| Starting | 2.5 mg weekly | 4 weeks |
| First increase | 5 mg weekly | 4 weeks (may maintain here) |
| Second increase | 7.5 mg weekly | 4 weeks |
| Third increase | 10 mg weekly | 4 weeks (may maintain here) |
| Fourth increase | 12.5 mg weekly | 4 weeks |
| Maximum | 15 mg weekly | Maintenance |
Dose titration is mandatory. Starting at higher doses causes severe GI side effects. The titration schedule increases by 2.5 mg every 4 weeks. Target maintenance dose (5, 10, or 15 mg) depends on individual response and tolerability.
Administration
Tirzepatide is administered as a once-weekly subcutaneous injection. Commercially available as pre-filled auto-injector pens (Mounjaro/Zepbound). Injection sites: abdomen, thigh, or upper arm — rotate sites weekly.
The injection can be given any day of the week, at any time, with or without meals. Choose a consistent day each week. If a dose is missed, administer within 4 days; if more than 4 days late, skip and resume on the next scheduled day.
Storage
Pre-filled pens must be refrigerated at 2-8°C (36-46°F). An unused pen can be kept at room temperature (up to 30°C/86°F) for up to 21 days. Do not freeze. Protect from light.
For research-grade lyophilized tirzepatide, use the peptide calculator for reconstitution and the storage guide for handling.